Contextual Genomics launch Phase 2 testing of its cancer genomics test
March 14, 2016 – VANCOUVER. Contextual Genomics, developers of genomics-based cancer tests, and the Personalized Medicine Initiative (PMI), an organization bringing molecular-based medicine to Canadians, have launched the National Access Program’s Phase 2 Testing of its Find It™ (CG001) hotspot cancer panel genomics test.
The National Access Program’s Phase 2 testing involves using Find It™ hotspot cancer panel genomics test to analyze the solid tumours of 1,500 patients across Canada. The Find It™ hotspot panel screens for 90 of the most common mutations found in many cancers. Based on the presence of a specific mutation in a cancer, healthcare providers can select the most appropriate treatment for the patient. The goal of the National Access Program is to make quality genomics testing widely available in cancer care to drive a shift towards personalized medicine and to support better health outcomes.
“We believe that quality genomic testing should become a standard practice in cancer care to give patients access to the most effective treatment option based on their tumour profile,” commented Chris Wagner, President and CEO of Contextual Genomics. “The National Access Program aims to make genomics cancer testing widely available in Canada. Our scientific expertise and CAP-accredited laboratory ensures that our genomics tests are of the highest standard of accuracy, relevance and safety,” he added.
Dr. David Huntsman, Chief Medical Officer of Contextual Genomics stated, “Contextual Genomics’ assays are designed to find the mutational information that oncologists and their patients need to make appropriate treatment decisions.” He added, “Treatments are being developed which focus on specific abnormalities and the Find It™ genomics test provides a breadth of valuable data which will help to determine if a patient will respond and benefit from a specific treatment.”
For Phase 2 of the National Access Program, Find It™ hotspot panel will be provided free of charge to 1,500 patients. Test results will be given to the oncologist in a comprehensive clinical report.
Source: Contextual Genomics